Organogenesis Holdings (ORGO) EBITDA (2016 - 2026)

Organogenesis Holdings' EBITDA history runs 11 years deep, the most recent figure standing at -$68.9 million for Q1 2026.

• On a quarterly basis, EBITDA fell 157.57% year-over-year to -$68.9 million in Q1 2026; TTM through Mar 2026 was $2.5 million, a 110.54% increase from a year earlier, with the FY2025 full-year figure at $44.7 million, up 3583.55% from the prior year.
• EBITDA retreated to -$68.9 million in Q1 2026 per ORGO's latest filing, from $63.3 million in the prior quarter.
• Across five years, EBITDA topped out at $63.3 million in Q4 2025 and bottomed at -$68.9 million in Q1 2026.
• The 5-year median for EBITDA is $1.8 million (2022), against an average of $549941.2.
• Across the five-year window, EBITDA sank 3025.78% in 2023 and soared 905.28% in 2024, its largest moves.
• Year by year, EBITDA stood at $8.7 million in 2022, then plunged by 114.56% to -$1.3 million in 2023, then surged by 905.28% to $10.2 million in 2024, then soared by 519.33% to $63.3 million in 2025, then sank by 208.85% to -$68.9 million in 2026.
• Per Business Quant, the three latest ORGO EBITDA figures stand at -$68.9 million (Q1 2026), $63.3 million (Q4 2025), and $20.7 million (Q3 2025).